Aplastic Anemia after Meprobamate (2-Methyl-2-N-Propyl-1,3-Propanediol Dicarbamate) Therapy

Publisher Website
Google Scholar
Abstract
MEPROBAMATE (Miltown), 2-methyl-2-n-propyl-1,3-propanediol dicarbamate, was recently introduced as a sedative and tranquilizing drug. In doses of one or two tablets (400 mg. each) three times a day, no adverse hematologic effects were noted after two months.1 Rare allergic reactions were reported by Selling.2 More recently Carmel and Dannenberg3 described 3 cases of nonthrombocytopenic purpura after ingestion of 400 to 1200 mg.In the following case aplastic anemia developed after daily ingestion of 1200 mg. for eight days.Case ReportF.D., a 28-year-old woman, was admitted to the South Nassau Communities Hospital on May 13, 1956, because of malaise, weakness, headache . . .